A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

NCT03530683 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

189

Enrollment

INDUSTRY

Sponsor class

Stopped A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.

Conditions

Lymphoma
Multiple Myeloma
Acute Myeloid Leukemia
Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Maplirpacept (PF-07901801)
DRUG: Azacitidine
DRUG: Venetoclax
DRUG: Carfilzomib
DRUG: Dexamethasone
DRUG: Anti-CD20 Targeting agent
DRUG: Isatuximab

Sponsor

Pfizer